HRP20150884T1 - Kombinacijska terapija koja ukljuäśuje antagoniste alfa5beta1 - Google Patents

Kombinacijska terapija koja ukljuäśuje antagoniste alfa5beta1 Download PDF

Info

Publication number
HRP20150884T1
HRP20150884T1 HRP20150884TT HRP20150884T HRP20150884T1 HR P20150884 T1 HRP20150884 T1 HR P20150884T1 HR P20150884T T HRP20150884T T HR P20150884TT HR P20150884 T HRP20150884 T HR P20150884T HR P20150884 T1 HRP20150884 T1 HR P20150884T1
Authority
HR
Croatia
Prior art keywords
antagonist antibody
disease
vegf
vegf antagonist
antibody
Prior art date
Application number
HRP20150884TT
Other languages
English (en)
Inventor
Anan Chuntharapai
Greg Plowman
Marc Tessier-Lavigne
Yan Wu
Weilan Ye
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of HRP20150884T1 publication Critical patent/HRP20150884T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Claims (19)

1. Protutijelo antagonista anti-VEGF, naznačeno time, da se upotrebljava u postupku liječenja bolesti koja ima prekomjernu angiogenezu kod pojedinca, pomoću davanja protutijela antagonista anti-VEGF i protutijela antagonista anti-alfa5beta1, pri čemu se protutijelo antagonista anti-VEGF i protutijelo antagonista anti-alfa5beta1 primjenjuju u sukladnim ciklusima liječenja.
2. Protutijelo antagonista anti-alfa5beta1, naznačeno time, da se upotrebljava u postupku liječenja bolesti koja ima prekomjernu angiogenezu kod pojedinca, pomoću davanja protutijela antagonista anti-VEGF i protutijela antagonista anti-alfa5beta1, pri čemu se protutijelo antagonista anti-VEGF i protutijelo antagonista anti-alfa5beta1 primjenjuju u sukladnim ciklusima liječenja.
3. Protutijelo antagonista anti-VEGF i protutijelo antagonista anti-alfa5beta1, naznačeni time, da se upotrebljavaju u postupku liječenja bolesti koja ima prekomjernu angiogenezu kod pojedinca, pomoću davanja protutijela antagonista anti-VEGF i protutijela antagonista anti-alfa5beta1, pri čemu se protutijelo antagonista anti-VEGF i protutijelo antagonista anti-alfa5beta1 primjenjuju u sukladnim ciklusima liječenja.
4. Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5beta1, za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen/i time, da se pojednincu dodatno daje terapeutsko sredstvo odabrano iz skupine koju čine: anti-neoplastično sredstvo, kemoterapeutsko sredstvo, inhibitor rasta i citotoksično sredstvo.
5. Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5beta1, za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen/i time, da je bolest odabrana iz skupine koja se sastoji od tumora, imunološke bolesti, ili pri kojoj pojedinac ima povišene razine alfa5beta1 u oboljelom tkivu, u usporedbi s tkivom kod pojedinca koji ne pati od bolesti.
6. Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5beta1, za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen/i time, da je bolest odabrana iz skupine koju čine: čvrsti tumor, metastazirajući tumor, tumor mekog tkiva, bolest koja uključuje očnu neovaskularizaciju, upalna bolest koja ima prekomjernu angiogenezu, bolest koja ima prekomjernu angiogenezu s porastom nakon transplantacije kod pojedinca i bolest koja ima nenormalnu proliferaciju fibrovaskularnog tkiva.
7. Protutijelo anti-VEGF i/ili protutijelo anti-alfa5beta1, za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen/i time, da bolest je rak, očna bolest ili autoimuna bolest.
8. Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5beta1, za uporabu prema zahtjevu 7, naznačen/i time, da je rak odabran iz skupine koju čine: rak dojke, rak cerviksa, kolorektalni rak, rak pluća, non-Hodgkinsov limfom (NHL), rak renalnih stanica, rak prostate, rak jetre, rak glave i vrata, melanom, rak jajnika, mezoteliom, rak mekog tkiva i višestruki mijelom.
9. Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5beta1, za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen/i time, da je bolest odabrana iz skupine koju čine: retinopatija, makularna degeneracija izazvana starošću, rubeoza, psorijaza, psorijatični artritis, upalna bolest bubrega, sindrom hemolitičke uremije, dijabetička nefropatija, artritis, upalna bolest crijeva, kronično zapaljenje, kronično odvajanje bubrega, kronični uveitis, kronični vitritis, odbijanje usatka rožnice, neovaskularizacija rožnice, neovaskularizacija usatka rožnice, Chronova bolest, miopija, očna neovaskularna bolest, osteoartritis, Pagetova bolest, pemfigoid, poliarteritis, post-laserska radijalna keratotomija, retinalna neovaskularizacija, Sjorgenov sindrom, ulcerativni kolitis, odbijanje usadaka, upala pluća, nefrotički sindrom, edem, ascites povezani s malignim poremećajima, udar, angiofibrom i neovaskularni glaukom.
10. Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5beta1, za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen/i time, da je protutijelo antagonista anti-alfa5beta1 konjugirano u citotoksično sredstvo.
11. Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5beta1, za uporabu prema zahtjevu 10, naznačen/i time, da citotoksično sredstvo je radioaktivni izotop, kemoterapeutsko sredstvo ili toksin.
12. Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5beta1, za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen/i time, da je protutijelo antagonista anti-VEGF humanizirano ili je to humano protutijelo.
13. Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5beta1, za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen/i time, da je protutijelo antagonista anti-alfa5beta1 humanizirano ili je to humano protutijelo.
14. Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5beta1, za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen/i time, da protutijelo antagonista anti-VEGF može biti kompetitivno spriječeno za spajanje na humani VEGF pomoću bevacizumaba.
15. Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5beta1, za uporabu prema zahtjevu 14, naznačen/i time, da protutijelo antagonista anti-VEGF je bevacizumab.
16. Uporaba protutijela antagonista anti-VEGF, naznačena time, da je za proizvodnju lijeka za liječenje bolesti koja ima prekomjernu angiogenezu kod pojedinca, pomoću davanja protutijela antagonista anti-VEGF i protutijela antagonista anti-alfa5beta1, pri čemu se protutijelo antagonista anti-VEGF i protutijelo antagonista anti-alfa5beta1 primjenjuju u sukladnim ciklusima liječenja.
17. Uporaba protutijela antagonista anti-alfa5beta1, naznačena time, da je za proizvodnju lijeka za liječenje bolesti koja ima prekomjernu angiogenezu kod pojedinca, pomoću davanja protutijela antagonista anti-VEGF i protutijela antagonista anti-alfa5beta1, pri čemu se protutijelo antagonista anti-VEGF i protutijelo antagonista anti-alfa5beta1 primjenjuju u sukladnim ciklusima liječenja.
18. Uporaba protutijela antagonista anti-VEGF i protutijela antagonista anti-alfa5beta1, naznačena time, da je za proizvodnju lijeka za liječenje bolesti koja ima prekomjernu angiogenezu kod pojedinca, pomoću davanja protutijela antagonista anti-VEGF i protutijela antagonista anti-alfa5beta1, pri čemu se protutijelo antagonista anti-VEGF i protutijelo antagonista anti-alfa5beta1 primjenjuju u sukladnim ciklusima liječenja.
19. Uporaba prema bilo kojem od zahtjeva 16 do 18, naznačena time, da je protutijelo antagonista anti-VEGF, protutijelo antagonista anti-alfa5beta1, pojedinac i/ili bolest, definirano/definiran/definirana prema bilo kojem od zahtjeva 4 do 15.
HRP20150884TT 2006-03-21 2015-08-19 Kombinacijska terapija koja ukljuäśuje antagoniste alfa5beta1 HRP20150884T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US78470406P 2006-03-21 2006-03-21
US78533006P 2006-03-22 2006-03-22
US87174306P 2006-12-22 2006-12-22
PCT/US2007/064572 WO2008060645A2 (en) 2006-03-21 2007-03-21 Combinatorial therapy involving alpha5beta1 antagonists
EP07868188.9A EP1989231B1 (en) 2006-03-21 2007-03-21 Combinatorial therapy involving alpha5beta1 antagonists

Publications (1)

Publication Number Publication Date
HRP20150884T1 true HRP20150884T1 (hr) 2015-09-25

Family

ID=39402298

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150884TT HRP20150884T1 (hr) 2006-03-21 2015-08-19 Kombinacijska terapija koja ukljuäśuje antagoniste alfa5beta1

Country Status (27)

Country Link
US (3) US20090220504A1 (hr)
EP (2) EP1989231B1 (hr)
JP (2) JP5298007B2 (hr)
KR (1) KR101454491B1 (hr)
AR (1) AR060040A1 (hr)
AU (1) AU2007319757B2 (hr)
BR (1) BRPI0709338A2 (hr)
CA (1) CA2646611A1 (hr)
CR (1) CR10311A (hr)
DK (1) DK1989231T3 (hr)
EC (1) ECSP088835A (hr)
ES (1) ES2544957T3 (hr)
HR (1) HRP20150884T1 (hr)
HU (1) HUE025989T2 (hr)
IL (1) IL193926A (hr)
MA (1) MA30384B1 (hr)
MX (1) MX2008011905A (hr)
MY (1) MY159375A (hr)
NO (1) NO20084396L (hr)
NZ (3) NZ571068A (hr)
PL (1) PL1989231T3 (hr)
PT (1) PT1989231E (hr)
RS (1) RS54156B1 (hr)
RU (1) RU2012129350A (hr)
TW (1) TWI397535B (hr)
UA (1) UA100969C2 (hr)
WO (1) WO2008060645A2 (hr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI397535B (zh) 2006-03-21 2013-06-01 Genentech Inc 包含α5β1拮抗劑之組合治療
AU2007253586A1 (en) * 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity
BRPI0813630A2 (pt) * 2007-07-27 2019-09-24 Facet Biotech Corp combinações farmacêuticas compreendendo inibidor da tirosina quinase e anticorpo contra a integrina alfa 1 beta 5 (cd49e)
TWI547503B (zh) 2007-09-26 2016-09-01 建南德克公司 抗α5β1抗體、編碼其之核酸、包含其之組合物及其製造及使用方法
CA2714071A1 (en) 2008-02-05 2009-08-13 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
AU2009331528A1 (en) 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
SG10201609416XA (en) * 2009-03-25 2016-12-29 Genentech Inc NOVEL ANTI-α5ß1 ANTIBODIES AND USES THEREOF
CN102253787B (zh) * 2010-05-21 2014-12-10 宸鸿科技(厦门)有限公司 电感式触控传感器及其触摸点侦测方法
ES2699532T3 (es) * 2011-03-23 2019-02-11 Univ California Métodos y composiciones para mejorar la terapia antiangiogénica con anti-integrinas
WO2013025936A1 (en) * 2011-08-18 2013-02-21 Cornell University Detection and treatment of metastatic disease
DK2847231T3 (da) 2012-05-10 2019-10-14 Bioatla Llc Multispecifikke monoklonale antistoffer
RS63212B1 (sr) * 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20180104635A (ko) 2015-12-30 2018-09-21 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2018106959A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112215A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
AU2022273290A1 (en) * 2021-05-11 2023-11-30 Pasithea Therapeutics Corp. Alpha 5 beta 1 integrin binding agents and uses thereof
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
AU3934085A (en) 1984-01-30 1985-08-09 Icrf Patents Ltd. Improvements relating to growth factors
US5540933A (en) * 1985-05-31 1996-07-30 La Jolla Cancer Research Foundation Isolation and use of fibronectin receptor
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
EP0330506A3 (en) * 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
WO1989012631A1 (en) 1988-06-24 1989-12-28 The Dow Chemical Company Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
PT90959B (pt) 1988-06-24 1995-05-04 Dow Chemical Co Processo para a preparacao de quelantes macrociclicos bifuncionais, de seus complexos e seus conjugados com anticorpos
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
WO1991005264A1 (en) 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US20020146410A1 (en) 1992-05-22 2002-10-10 Helmut Eckert Monoclonal antibodies and their use
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5627263A (en) * 1993-11-24 1997-05-06 La Jolla Cancer Research Foundation Integrin-binding peptides
ES2202336T3 (es) * 1994-12-20 2004-04-01 Merck Patent Gmbh Anticuerpo monoclonal contra la integrina alfa-v.
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
ATE433495T1 (de) 1996-11-21 2009-06-15 Univ Michigan Invasionsinhibitoren zur verwendung in der wundheilung und krebsbehandlung
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE69810481T2 (de) 1997-06-13 2003-09-25 Genentech Inc Stabilisierte antikörperformulierung
HUP0101151A3 (en) 1998-01-23 2004-06-28 Merck Patent Gmbh Monoclonal antibody anti alphav-integrin and its use to inhibit alphavbetha6-integrin attachment to fibnronectin
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
EP2044955A3 (en) 1998-05-08 2009-04-29 The Regents of the University of California Methods for detecting and inhibiting angiogenesis
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
GB9909392D0 (en) 1999-04-24 1999-06-23 Imp Cancer Res Tech Treatment, imaging and diagnosis of disease
US20040009494A1 (en) * 1999-08-11 2004-01-15 Richard Murray Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators
JP2003517816A (ja) 1999-08-11 2003-06-03 イオス バイオテクノロジー， インコーポレイテッド 新脈管形成の診断の新規方法、新脈管形成調節因子についてのスクリーニングの組成物および方法
US20030152926A1 (en) * 1999-08-11 2003-08-14 Eos Biotechnology, Inc. Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20020015970A1 (en) * 1999-08-11 2002-02-07 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20020019330A1 (en) * 1999-08-11 2002-02-14 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20040259152A1 (en) * 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
EP1418943A1 (en) 2001-02-14 2004-05-19 Protein Design Labs, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
WO2002086443A2 (en) 2001-04-18 2002-10-31 Protein Design Labs, Inc Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002314901A1 (en) * 2001-06-04 2002-12-16 Eos Biotechnology, Inc. Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
AU2002347428A1 (en) 2001-06-18 2003-01-02 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20040033495A1 (en) * 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20070042360A1 (en) * 2001-09-17 2007-02-22 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20030232350A1 (en) * 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
AU2003256307A1 (en) * 2002-06-25 2004-01-06 The Regents Of The University Of California Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival
JP4741242B2 (ja) * 2002-11-26 2011-08-03 アボット バイオセラピューティクス コーポレイション 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体
US20040253606A1 (en) * 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
NZ541503A (en) * 2003-01-22 2008-09-26 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
EP1625165A2 (en) * 2003-04-03 2006-02-15 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US7194111B1 (en) * 2003-07-10 2007-03-20 The United States Of America As Represented By The Secretary Of The Navy Hyperspectral remote sensing systems and methods using covariance equalization
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
ATE531388T1 (de) * 2004-03-24 2011-11-15 Abbott Biotherapeutics Corp Verwendung von anti-alpha5beta1-antikörpern zur hemmung der krebszellproliferation
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
EA013323B1 (ru) * 2004-12-09 2010-04-30 Сентокор, Инк. Иммуноконъюгаты против интегрина, способы и варианты применения
JP2009516729A (ja) 2005-11-23 2009-04-23 アストラゼネカ アクチボラグ Ｌ−フェニルアラニン誘導体
US20090111828A1 (en) * 2005-11-23 2009-04-30 Astrazeneca Ab L-alanine derivatives
WO2007091046A1 (en) 2006-02-09 2007-08-16 Astrazeneca Ab Chemical compounds
TWI397535B (zh) 2006-03-21 2013-06-01 Genentech Inc 包含α5β1拮抗劑之組合治療
AU2007253586A1 (en) 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity

Also Published As

Publication number Publication date
IL193926A0 (en) 2011-08-01
EP1989231B1 (en) 2015-05-20
TW200813090A (en) 2008-03-16
KR101454491B1 (ko) 2014-10-29
AR060040A1 (es) 2008-05-21
EP2366716A3 (en) 2011-11-16
NZ598594A (en) 2014-01-31
MX2008011905A (es) 2008-09-30
IL193926A (en) 2015-05-31
EP1989231A2 (en) 2008-11-12
DK1989231T3 (en) 2015-08-24
MY159375A (en) 2016-12-30
JP2013155178A (ja) 2013-08-15
HUE025989T2 (hu) 2016-05-30
ES2544957T3 (es) 2015-09-07
US20090220504A1 (en) 2009-09-03
RS54156B1 (en) 2015-12-31
WO2008060645A3 (en) 2008-12-04
CR10311A (es) 2009-01-20
US20120195908A1 (en) 2012-08-02
NO20084396L (no) 2008-12-16
AU2007319757B2 (en) 2013-09-19
NZ571068A (en) 2012-06-29
NZ615012A (en) 2015-11-27
KR20080113246A (ko) 2008-12-29
EP2366716A2 (en) 2011-09-21
MA30384B1 (fr) 2009-05-04
JP2009536921A (ja) 2009-10-22
JP5298007B2 (ja) 2013-09-25
UA100969C2 (uk) 2013-02-25
AU2007319757A1 (en) 2008-05-22
BRPI0709338A2 (pt) 2011-07-12
ECSP088835A (es) 2008-11-27
US8350010B2 (en) 2013-01-08
TWI397535B (zh) 2013-06-01
WO2008060645A2 (en) 2008-05-22
CA2646611A1 (en) 2008-05-22
US20140004038A1 (en) 2014-01-02
PT1989231E (pt) 2015-09-18
RU2012129350A (ru) 2014-01-20
PL1989231T3 (pl) 2015-10-30

Similar Documents

Publication Publication Date Title
HRP20150884T1 (hr) Kombinacijska terapija koja ukljuäśuje antagoniste alfa5beta1
HRP20171758T1 (hr) Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene
A Baudino Targeted cancer therapy: the next generation of cancer treatment
JP6130871B2 (ja) Ｃｄ３８を特異的に認識する抗体とビンクリスチンとを含有する抗腫瘍組合せ
JP2009536921A5 (hr)
JP2013512254A5 (hr)
JP2018184417A5 (hr)
JP2019506403A5 (hr)
RU2013102225A (ru) АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2018534933A5 (hr)
HRP20190817T1 (hr) Ang2-vezujuće molekule
JP2017533912A5 (hr)
JP2011046732A5 (hr)
JP2016528162A5 (hr)
HRP20150256T1 (hr) Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe
Langer et al. The Role of Anti–Epidermal Growth Factor Receptor and Anti–Vascular Endothelial Growth Factor Therapies in the Treatment of Non–Small-Cell Lung Cancer
US9388239B2 (en) Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
RU2015144666A (ru) Терапия для лечения рака, включающая антитела против клаудина 18.2
HRP20220399T1 (hr) Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost
JP2009539870A5 (hr)
JP2014504866A5 (hr)
JP2010540449A5 (hr)
RU2018102963A (ru) Производные анилинпиримидина и их применения
JP6449772B2 (ja) ヒト抗ｖｅｇｆｒ２／ｋｄｒ抗体
JP2019517485A5 (hr)